Amneal Pharmaceuticals filed a prospectus with the US Securities and Exchange Commission (SEC) on August 14, 2026. The filing relates to the proposed offer and sale of shares by existing selling stockholders.

The prospectus covers the potential sale of up to 28,942,098 shares of the company’s Class A common stock. The document outlines the terms under which these shares may be offered to investors.

Filing Details

The registration statement was submitted to facilitate the liquidity event for the selling stockholders. No financial performance metrics or operational updates were included in this specific filing.

Amneal Pharmaceuticals Inc. completed its acquisition of Kashiv BioSciences LLC on Aug. 10, 2026, creating one of the industry’s few fully integrated global biosimilars platforms. The transaction combines Kashiv’s biologics research, development, and manufacturing capabilities with Amneal’s commercial scale, positioning the combined entity to capitalize on more than $300 billion in projected global biologics loss-of-exclusivity over the next decade. This strategic move establishes biosimilars as a major long-term growth pillar for Amneal, extending its growth profile into the 2030s and supporting a consistent cadence of biosimilar launches.

The acquisition integrates end-to-end capabilities across research, development, manufacturing, and commercialization. Chirag Patel, Co-Founder and Co-Chief Executive Officer of Amneal, stated that the completion marks a pivotal step in the company’s strategy to become America’s number one Affordable Medicines company. The combined entity aims to launch multiple biosimilars each year, leveraging the integrated platform to expand patient access to high-quality, affordable biologic medicines.

Chintu Patel, Co-Founder and Co-Chief Executive Officer, welcomed the Kashiv team and thanked shareholders for their support. He emphasized that the acquisition positions Amneal to capitalize on an unprecedented wave of biologic loss of exclusivity. The integration planning is already underway, focusing on combining development and manufacturing capabilities and advancing the biosimilar pipeline. This builds on a relationship between Amneal and Kashiv spanning more than a decade.

Transaction Advisors

Several financial and legal advisors facilitated the transaction for both parties:

Richards, Layton & Finger, P.A. served as legal counsel to the Committee of Independent Directors of Amneal’s Board of Directors. Dhinal Shah Associates served as an advisor in India to Kashiv.

What the Numbers Show

The primary material impact of this transaction is structural rather than immediately quantitative in terms of revenue or profit figures disclosed in this announcement. However, the scale of the opportunity is defined by the $300 billion projected global biologics loss-of-exclusivity market over the next decade. By acquiring Kashiv, Amneal gains immediate access to this market through a vertically integrated platform, reducing reliance on third-party manufacturers for its biosimilar portfolio. This integration allows Amneal to control the entire value chain from R&D to commercialization, potentially improving margins and speed-to-market for future biosimilar launches compared to non-integrated competitors.

About the Companies

Amneal Pharmaceuticals Inc., headquartered in Bridgewater, New Jersey, is a diversified global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Founded in 2002 by brothers Chirag and Chintu Patel, Amneal has a portfolio of approximately 300 complex generic, specialty, and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Its segments include Affordable Medicines, Specialty, and AvKARE.

Kashiv BioSciences LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets. It is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv operates with robust infrastructure and skilled teams providing global R&D, clinical, manufacturing, regulatory, and IP capabilities through its U.S. operations and subsidiaries in India.